Jayoung Kim1, Susan K Keay, Michael R Freeman. 1. The Urological Diseases Research Center, Children's Hospital Boston, Boston, MA, USA. ja.kim@childrens.harvard.edu
Abstract
OBJECTIVE: To delineate the mechanism underlying the potential functional relationship between interstitial cystitis antiproliferative factor (APF) and heparin-binding epidermal growth factor-like growth factor (HB-EGF), as APF has previously been shown to decrease the proliferation rate of normal bladder epithelial cells and the amount of HB-EGF produced by these cells. MATERIALS AND METHODS: APF-responsive T24 transitional carcinoma bladder cells were treated with high-pressure liquid chromatography-purified native APF with or without HB-EGF to determine the involvement of signalling pathways and proliferation by Western blot analysis, p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (Erk)/MAPK assays, and 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay. RESULTS: Cyclic stretch induced the secretion of HB-EGF from T24 cells overexpressing the HB-EGF precursor, resulting in enhanced proliferation. T24 cells treated with APF had increased p38MAPK activity and suppressed cell growth, events that were both reversed by treatment with a p38MAPK-selective inhibitor. Activation of Erk/MAPK by HB-EGF was inhibited by APF, and APF did not stimulate p38MAPK in the presence of soluble HB-EGF or when cells overexpressed constitutively secreted HB-EGF. Lastly, APF inhibitory effects on cell growth were attenuated by HB-EGF. CONCLUSIONS: These results indicate that HB-EGF and APF are functionally antagonistic and signal through parallel MAPK signalling pathways in bladder cells.
OBJECTIVE: To delineate the mechanism underlying the potential functional relationship between interstitial cystitis antiproliferative factor (APF) and heparin-binding epidermal growth factor-like growth factor (HB-EGF), as APF has previously been shown to decrease the proliferation rate of normal bladder epithelial cells and the amount of HB-EGF produced by these cells. MATERIALS AND METHODS: APF-responsive T24 transitional carcinoma bladder cells were treated with high-pressure liquid chromatography-purified native APF with or without HB-EGF to determine the involvement of signalling pathways and proliferation by Western blot analysis, p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (Erk)/MAPK assays, and 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay. RESULTS: Cyclic stretch induced the secretion of HB-EGF from T24 cells overexpressing the HB-EGF precursor, resulting in enhanced proliferation. T24 cells treated with APF had increased p38MAPK activity and suppressed cell growth, events that were both reversed by treatment with a p38MAPK-selective inhibitor. Activation of Erk/MAPK by HB-EGF was inhibited by APF, and APF did not stimulate p38MAPK in the presence of soluble HB-EGF or when cells overexpressed constitutively secreted HB-EGF. Lastly, APF inhibitory effects on cell growth were attenuated by HB-EGF. CONCLUSIONS: These results indicate that HB-EGF and APF are functionally antagonistic and signal through parallel MAPK signalling pathways in bladder cells.
Authors: J E Tomaszewski; J R Landis; V Russack; T M Williams; L P Wang; C Hardy; C Brensinger; Y L Matthews; S T Abele; J W Kusek; L M Nyberg Journal: Urology Date: 2001-06 Impact factor: 2.649
Authors: Hani H Rashid; Jay E Reeder; Mary J O'Connell; Chen-Ou Zhang; Edward M Messing; Susan K Keay Journal: BMC Urol Date: 2004-04-06 Impact factor: 2.264
Authors: Kristopher R Koch; Chen-Ou Zhang; Piotr Kaczmarek; Joseph Barchi; Li Guo; Hanief M Shahjee; Susan Keay Journal: Invest New Drugs Date: 2011-09-20 Impact factor: 3.850
Authors: Wei Yang; Yongsoo Kim; Taek-Kyun Kim; Susan K Keay; Kwang Pyo Kim; Hanno Steen; Michael R Freeman; Daehee Hwang; Jayoung Kim Journal: BJU Int Date: 2012-06-28 Impact factor: 5.588
Authors: Susan Keay; Piotr Kaczmarek; Chen-Ou Zhang; Kristopher Koch; Zoltan Szekely; Joseph J Barchi; Christopher Michejda Journal: Chem Biol Drug Des Date: 2011-04-27 Impact factor: 2.817